BioCatalyst

ARGX — ARGENX SE catalysts

2 verified catalyst event(s) for ARGENX SE (ticker ARGX). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-10-01 — A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in A · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10-01
in 11d
ESTIMATED
 READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia
 ARGX ARGENX SE efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-11 (month)
in 1mo
ESTIMATED
 READOUT
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom
Phase 2 · Dermatomyositis, Myositis
 ARGX ARGENX SE Empasiprubart IV ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.